Drug Trial Radar · NCT06524375
A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
118
Actual
Start
Aug 9, 2024
Primary completion
Oct 28, 2026
Study completion Jan 31, 2030
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.
Conditions
- Chronic Lymphocytic Leukemia
Interventions
VenetoclaxDrug
Venetoclax tablets will be administered as per the schedule specified in the arm.
cBTKi MonotherapyDrug
Commercially available cBTKi (ibrutinib or acalabrutinib, or zanubrutinib) will be administered in accordance with its prescribing label.
Primary outcomes
What the sponsor says the trial is designed to measure.
- uMRD4 Rate at EOCTTime frame: Cycle 12 Day 28 (Cycle length= 28 Days)
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Highlands Oncology Group
Springdale, Arkansas
Rocky Mountain Cancer Centers (Aurora) - USOR
Aurora, Colorado
Cancer Specialists of North Florida
Jacksonville, Florida
Fort Wayne Medical Oncology and Hematology, Inc
Fort Wayne, Indiana
Mission Blood and Cancer - MercyOne Cancer Center
Des Moines, Iowa
American Oncology Partners of Maryland, PA
Bethesda, Maryland
Dana-Farber Cancer Institute - Hematologic Oncology Treatment Center
Boston, Massachusetts
Nebraska Cancer Specialists St Francis - Grand Island
Grand Island, Nebraska
Nebraska Cancer Specialists
Omaha, Nebraska
Astera Cancer Care East Brunswick
East Brunswick, New Jersey
San Juan Oncology Associates, PC
Farmington, New Mexico
Oncology Hematology Care Inc - Cincinnati - USOR
Cincinnati, Ohio
Ohio State University
Columbus, Ohio
Willamette Valley Cancer Institute and Research Center
Eugene, Oregon
Asante Rogue Regional Medical Center
Medford, Oregon
Tennessee Oncology, PLLC - Chattanooga
Chattanooga, Tennessee
Tennessee Oncology - Midtown
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Texas Oncology- Northeast Texas
Tyler, Texas
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.